OCA
NEUP

Octagon Capital Advisors’s Neuphoria Therapeutics NEUP Stock Holding History

Octagon Capital Advisors’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-14,000
Closed -$454K – 49
2023
Q3 		$454K Buy
+14,000
New +$302K 0.07% 39

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Octagon Capital Advisors's NEUP Position: Q4 2023 in Review

Octagon Capital Advisors sold out of Neuphoria Therapeutics (NEUP) in Q4 2023, closing a stake of 14,000 shares — an estimated $454K sold.

Octagon Capital Advisors first reported a position in NEUP in Q3 2023 and held it in 1 quarter. The position peaked at $454K in Q3 2023. 9 funds tracked by Wall St. Rank hold NEUP as of Q4 2023.

  • Octagon Capital Advisors reported no remaining Neuphoria Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Octagon Capital Advisors sold 14,000 Neuphoria Therapeutics shares in Q4 2023, an estimated $454K.
  • Octagon Capital Advisors first reported a position in Neuphoria Therapeutics in Q3 2023 and held it in 1 quarter.
  • Octagon Capital Advisors's Neuphoria Therapeutics position peaked at $454K in Q3 2023.
  • 9 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q4 2023.

Based on Octagon Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.